Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gross Profit (2020 - 2025)

Insight Molecular Diagnostics' Gross Profit history spans 6 years, with the latest figure at $139000.0 for Q3 2025.

  • For Q3 2025, Gross Profit rose 178.0% year-over-year to $139000.0; the TTM value through Sep 2025 reached $2.4 million, up 8503.57%, while the annual FY2024 figure was $740000.0, 79.18% up from the prior year.
  • Gross Profit for Q3 2025 was $139000.0 at Insight Molecular Diagnostics, down from $350000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $2.6 million in Q4 2021 and bottomed at -$866000.0 in Q3 2021.
  • The 5-year median for Gross Profit is $50000.0 (2024), against an average of $211789.5.
  • The largest annual shift saw Gross Profit tumbled 333.33% in 2023 before it surged 2844.44% in 2025.
  • A 5-year view of Gross Profit shows it stood at $2.6 million in 2021, then tumbled by 101.04% to -$27000.0 in 2022, then tumbled by 333.33% to -$117000.0 in 2023, then soared by 608.55% to $595000.0 in 2024, then plummeted by 76.64% to $139000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Gross Profit are $139000.0 (Q3 2025), $350000.0 (Q2 2025), and $1.3 million (Q1 2025).